Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide

Table 1

Demographic and clinical characteristics of the study subjects stratified according to treatment.

Characteristics	Exenatide (𝑛=10)	Liraglutide (𝑛=10)	𝑃
Age (years)	45.2±11.4	54.6±12.9	0.143
Diabetes duration (years)	2.40±2.17	2.50±2.32	0.922
Hypertension	3 (yes)/7 (no)	4 (yes)/6 (no)	1.000*
Metformin use	9 (yes)/1 (no)	10 (yes)/0 (no)	1.000*
HbA1c (mmol/mol)	41.53±10.17	42.74±6.97	0.912
WHR (waist-to-hip ratio)	1.01±0.13	0.98±0.08	0.393
BMI (kg/m^2)	37.18±5.82	37.11±5.09	1.000
HbA1c (mmol/mol)	41.53±10.17	42.73±6.97	0.915

Data are means ± SD. (𝑃 indicates the result of the Mann-Whitney test between the two groups; ∗the result of Fisher’s exact test for differences between the two groups).